Health and Healthcare
5865 Articles
AnaptysBio has amended its filing with the U.S. Securities and Exchange Commission (SEC) regarding its initial public offering (IPO).
The short interest data have been released for the April 29 settlement date, and for most of the selected pharmaceutical…
The short interest data are out for the April 29 settlement date, and short interest moves were mixed in these…
Anacor Pharmaceuticals reported its first-quarter financial results before the markets opened on Tuesday.
A Merrill Lynch report has a whole wave of companies featured as Global Ageing Primer Picks, including these biotech and…
Merus plans to offer more than 4 million shares within an expected price range of $14 to $16 per share…
Theravance Biopharma has announced that the FDA approved its supplemental New Drug Application for Vibativ (telavancin) to expand the product's…
Horizon Pharma reported better-than-expected first-quarter financial results before the markets opened on Monday.
A research report from Janney's Roy Buchanan issued on Friday included a fair value estimate for Geron shares that was…
When Endo International reported its first-quarter financial results on Thursday, earnings vastly underwhelmed, and analysts definitely had something to say…
Several big FDA decisions should be coming up in the June quarter for the likes of AstraZeneca and Sarepta Therapeutics.
One time when missing earnings estimates doesn't matter much is when there is bidding war for the company. That's the…
Intellia Therapeutics entered the market with a bang on Friday, blowing out its expected price range of $16 to $18.
Endo International reported mixed first-quarter financial results after the markets closed on Thursday.
Pernix Therapeutics saw its shares hit a 52-week low in regular trading on Thursday after it reported its first-quarter financial…
Our top personal finance-related articles today. Your wallet will thank you later.